DDInter255 DDInter342
Busulfan is a bifunctional alkylating agent, having a selective immunosuppressive effect on bone marrow. It is not a structural analog of the nitrogen mustards. It has been used in the palliative treatment of chronic myeloid leukemia (myeloid leukemia, chronic), but although symptomatic relief is provided, no permanent remission is brought about. According to the Fourth Annual Report on Carcinogens (NTP 85-002, 1985), busulfan is listed as a known carcinogen.
Certolizumab pegol is a pegylated monoclonal antibody against the tumor necrosis factor-alpha (TNF-alpha). It is formed with a humanized Fab fragment of 50 kDa, from an IgG 1 isotype, fused to a 40 kDa polyethylene glycol moiety replacing the Fc antibody region. The absence of the Fc region was ideated to prevent complement fixation and antibody-mediated cytotoxicity as well as to markedly increase its half-life. Certolizumab does not require glycosylation for active function and hence, its production is significantly more affordable when compared to other existing TNF-alpha therapies as it can be done directly in bacterial hosts such as _E. coli_. It was developed and manufactured by UCB Pharma, first FDA approved in 2008 and updated for a new indication on March 28, 2019.
Busulfan {u} (Compound) binds {v} (Gene) GSTA2
GSTA2 {u} (Gene) is bound by {v} (Compound) Vitamin E
Vitamin E {u} may cause a minor interaction that can limit clinical effects when taken with {v} Certolizumab pegol
Busulfan {u} (Compound) downregulates {v} (Gene) PIN1
PIN1 {u} (Gene) is downregulated by {v} (Compound) Stavudine
Stavudine {u} may cause a moderate interaction that could exacerbate diseases when taken with {v} Certolizumab pegol
Busulfan {u} (Compound) binds {v} (Gene) GSTP1
GSTP1 {u} (Gene) is bound by {v} (Compound) Etoposide
Etoposide {u} may lead to a major life threatening interaction when taken with {v} Certolizumab pegol
Busulfan {u} (Compound) causes {v} (Side Effect) Gastrointestinal pain
Gastrointestinal pain {u} (Side Effect) is caused by {v} (Compound) Stavudine
Stavudine {u} may cause a moderate interaction that could exacerbate diseases when taken with {v} Certolizumab pegol
Busulfan {u} (Compound) downregulates {v} (Gene) TNIP1
TNIP1 {u} (Gene) is upregulated by {v} (Compound) Crizotinib
Crizotinib {u} may cause a moderate interaction that could exacerbate diseases when taken with {v} Certolizumab pegol
Busulfan {u} (Compound) downregulates {v} (Gene) PIN1
PIN1 {u} (Gene) is downregulated by {v} (Compound) Budesonide
Budesonide {u} may lead to a major life threatening interaction when taken with {v} Certolizumab pegol
Busulfan {u} (Compound) downregulates {v} (Gene) TNIP1
TNIP1 {u} (Gene) is upregulated by {v} (Compound) Teniposide
Teniposide {u} may lead to a major life threatening interaction when taken with {v} Certolizumab pegol
Busulfan {u} (Compound) causes {v} (Side Effect) Neurological symptom
Neurological symptom {u} (Side Effect) is caused by {v} (Compound) Lomustine
Lomustine {u} may lead to a major life threatening interaction when taken with {v} Certolizumab pegol
Busulfan {u} (Compound) binds {v} (Gene) CYP3A4
CYP3A4 {u} (Gene) is bound by {v} (Compound) Fentanyl
Fentanyl {u} may cause a moderate interaction that could exacerbate diseases when taken with {v} Certolizumab pegol
Busulfan {u} (Compound) treats {v} (Disease) hematologic cancer
hematologic cancer {u} (Disease) is treated by {v} (Compound) Nilotinib
Nilotinib {u} may lead to a major life threatening interaction when taken with {v} Certolizumab pegol
Busulfan (Compound) binds GSTA2 (Gene) and GSTA2 (Gene) is bound by Vitamin E (Compound) and Vitamin E may cause a minor interaction that can limit clinical effects when taken with Certolizumab pegol
Busulfan (Compound) downregulates PIN1 (Gene) and PIN1 (Gene) is downregulated by Stavudine (Compound) and Stavudine may cause a moderate interaction that could exacerbate diseases when taken with Certolizumab pegol
Busulfan (Compound) binds GSTP1 (Gene) and GSTP1 (Gene) is bound by Etoposide (Compound) and Etoposide may lead to a major life threatening interaction when taken with Certolizumab pegol
Busulfan (Compound) causes Gastrointestinal pain (Side Effect) and Gastrointestinal pain (Side Effect) is caused by Stavudine (Compound) and Stavudine may cause a moderate interaction that could exacerbate diseases when taken with Certolizumab pegol
Busulfan (Compound) downregulates TNIP1 (Gene) and TNIP1 (Gene) is upregulated by Crizotinib (Compound) and Crizotinib may cause a moderate interaction that could exacerbate diseases when taken with Certolizumab pegol
Busulfan (Compound) downregulates PIN1 (Gene) and PIN1 (Gene) is downregulated by Budesonide (Compound) and Budesonide may lead to a major life threatening interaction when taken with Certolizumab pegol
Busulfan (Compound) downregulates TNIP1 (Gene) and TNIP1 (Gene) is upregulated by Teniposide (Compound) and Teniposide may lead to a major life threatening interaction when taken with Certolizumab pegol
Busulfan (Compound) causes Neurological symptom (Side Effect) and Neurological symptom (Side Effect) is caused by Lomustine (Compound) and Lomustine may lead to a major life threatening interaction when taken with Certolizumab pegol
Busulfan (Compound) binds CYP3A4 (Gene) and CYP3A4 (Gene) is bound by Fentanyl (Compound) and Fentanyl may cause a moderate interaction that could exacerbate diseases when taken with Certolizumab pegol
Busulfan (Compound) treats hematologic cancer (Disease) and hematologic cancer (Disease) is treated by Nilotinib (Compound) and Nilotinib may lead to a major life threatening interaction when taken with Certolizumab pegol